- Home
- TCRT vs RDHL Comparison
TCRT vs RDHL Comparison
Compare TCRT & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- RDHL
- Stock Information
- Founded
- TCRT 1998
- RDHL 2009
- Country
- TCRT United States
- RDHL Israel
- Employees
- TCRT N/A
- RDHL N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- RDHL Health Care
- Exchange
- TCRT Nasdaq
- RDHL Nasdaq
- Market Cap
- TCRT 3.8M
- RDHL 3.8M
- IPO Year
- TCRT N/A
- RDHL N/A
- Fundamental
- Price
- TCRT $3.03
- RDHL $1.99
- Analyst Decision
- TCRT
- RDHL
- Analyst Count
- TCRT 0
- RDHL 0
- Target Price
- TCRT N/A
- RDHL N/A
- AVG Volume (30 Days)
- TCRT 12.3K
- RDHL 214.4K
- Earning Date
- TCRT 05-15-2025
- RDHL 04-10-2025
- Dividend Yield
- TCRT N/A
- RDHL N/A
- EPS Growth
- TCRT N/A
- RDHL N/A
- EPS
- TCRT N/A
- RDHL N/A
- Revenue
- TCRT $11,000.00
- RDHL $8,042,999.00
- Revenue This Year
- TCRT $5,680,500.00
- RDHL $381.91
- Revenue Next Year
- TCRT N/A
- RDHL N/A
- P/E Ratio
- TCRT N/A
- RDHL N/A
- Revenue Growth
- TCRT 83.33
- RDHL 23.17
- 52 Week Low
- TCRT $1.31
- RDHL $1.71
- 52 Week High
- TCRT $11.00
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- TCRT 60.98
- RDHL 51.03
- Support Level
- TCRT $2.50
- RDHL $1.82
- Resistance Level
- TCRT $2.80
- RDHL $1.93
- Average True Range (ATR)
- TCRT 0.21
- RDHL 0.08
- MACD
- TCRT 0.01
- RDHL 0.04
- Stochastic Oscillator
- TCRT 98.31
- RDHL 100.00
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.